ReNerve (ASX:RNV) is working with US-based Berkeley Biologics to develop and commercialize two new tissue-based product ranges, according to a Monday filing with the Australian bourse.
The companies entered an initial five-year supply agreement for the product ranges, with the possibility of extension, as part of the collaboration, the filing said.
ReNerve plans to launch the first product line in the third quarter of the year and the second before the year ends, according to the filing.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。